Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Study: Antibody-directed chemotherapy may be effective for majority of younger AML sufferers

Antibody-directed chemotherapy offers improved survival to particular sub-groups of leukaemia sufferers, a Cardiff University-led study has found.

23 Feb 2011

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.

22 Feb 2011

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase 1b clinical trial of FT1050 at the 2011 BMT Tandem Meetings in Honolulu, Hawaii.

22 Feb 2011

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.

21 Feb 2011

International study shows reprogramming cells lead to genomic aberrations

It's a discordant note in the symphony of good news that usually accompanies stem cell research announcements. Stem cells hold enormous promise in regenerative medicine, thanks to their ability to regenerate diseased or damaged tissues.

21 Feb 2011

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has signed a licensing agreement with Biocare Medical, a biotechnology company based in Concord, Calif., for the exclusive worldwide sales and distribution rights for the immunohistochemistry of an antibody designed to detect tumor prevalence in prostate cancer patients.

18 Feb 2011

Researchers identify CD19-L protein that facilitates recognition, destruction of leukemia cells

Scientists at the Children's Center for Cancer and Blood Diseases and The Saban Research Institute of Children's Hospital Los Angeles today announced a breakthrough discovery in understanding how the body fights leukemia.

18 Feb 2011

Frequent, potentially avoidable readmissions are major driver of pediatric health care costs

Among a group of children's hospitals, nearly 20 percent of admissions and one-quarter of inpatient expenditures were accounted for by a small percentage of patients who have frequent recurrent admissions, according to a study in the February 16 issue of JAMA.

18 Feb 2011

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.

18 Feb 2011

TI Pharma launches new research project on stem cell transplant

Top Institute Pharma is today launching a new research project that should make stem cell transplants more successful. A stem cell transplant is usually performed on adults with acute leukemia.

18 Feb 2011

Loyola offers stem cell transplants to older patients with leukemia and lymphoma

As the first baby boomers turn 65, Loyola University Hospital has begun offering stem cell transplants to leukemia and lymphoma patients who previously were too old to qualify.

18 Feb 2011

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

Halozyme Therapeutics, Inc. and Roche today announced the first patient received subcutaneous MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze technology.

16 Feb 2011

AML patient raises awareness in community about national stem cell registry

By the age of 28, Dana Severson was already an Iraq war veteran, an accomplished clinical engineer, a wife and mother. Days following her daughter Genevieve's first birthday, Severson was faced with a reality that would turn her life upside down. After several weeks of experiencing severe headaches and extreme exhaustion, the young mother was diagnosed with acute myeloid leukemia.

16 Feb 2011

Researchers identify cell of origin for sarcoma

Researchers at Oregon Health & Science University Doernbecher Children's Hospital have defined the cell of origin for a kind of cancer called sarcoma. In a study published today as the Featured Article in the journal Cancer Cell, they report that childhood and adult sarcomas are linked in their biology, mutations and the cells from which these tumors first start.

16 Feb 2011

Researchers use computers to capture chemical signal structure that triggers metastatic cancer

In cancer and other pathological diseases, researchers are discovering that packaging is important: specifically, how DNA - about two meters long when unwound and stretched - coils up and compacts neatly inside the nucleus of a cell.

15 Feb 2011

Cord Blood America purchases minority interest in Stem Cells VIDAPLUS

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it has purchased a minority interest in Stem Cells VIDAPLUS, a Spanish-owned company which preserves umbilical cord stem cells at the Institute of Transfusion Medicine and Immunology of the Red Cross in Frankfurt, Germany.

14 Feb 2011

Silent strokes can cause long-term cognitive, learning deficits in children with sickle cell disease

Silent strokes, which have no immediate symptoms but could cause long-term cognitive and learning deficits, occur in a significant number of severely anemic children, especially those with sickle cell disease, according to research presented at the American Stroke Association's International Stroke Conference 2011.

13 Feb 2011

More research needed to determine link between folic acid and breast cancer

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

Cell Medica, a leading UK cellular therapeutics company that develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, announces today that the first patient has been treated in the CMV~ACE/ASPECT trial at University College Hospital London.

10 Feb 2011

bcl3 gene limits lung injury during acute stress from illness, trauma, transplant

Lung injury is a common cause of death among patients with pneumonia, sepsis or trauma and in those who have had lung transplants. The damage often occurs suddenly and can cause life-threatening breathing problems and rapid lung failure.

9 Feb 2011

Leukemia News and Research

Further Reading

Study: Antibody-directed chemotherapy may be effective for majority of younger AML sufferers

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

International study shows reprogramming cells lead to genomic aberrations

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

Researchers identify CD19-L protein that facilitates recognition, destruction of leukemia cells

Frequent, potentially avoidable readmissions are major driver of pediatric health care costs

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

TI Pharma launches new research project on stem cell transplant

Loyola offers stem cell transplants to older patients with leukemia and lymphoma

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

AML patient raises awareness in community about national stem cell registry

Researchers identify cell of origin for sarcoma

Researchers use computers to capture chemical signal structure that triggers metastatic cancer

Cord Blood America purchases minority interest in Stem Cells VIDAPLUS

Silent strokes can cause long-term cognitive, learning deficits in children with sickle cell disease

More research needed to determine link between folic acid and breast cancer

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

bcl3 gene limits lung injury during acute stress from illness, trauma, transplant

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News